Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 2 - Studien 11 bis 20 von insgesamt 88
- Rekrutierung läuftA non-interventional study for Kisqali (Ribociclib) in combination with an aromatase inhibitor in patients with HR+/HER2- stage II and III early breast cancer to evaluatereal-world effectiveness, safety profile, patient compliance and quality of life (CAROLEEN).Molekulare Marker
- Rekrutierung läuftLangzeitnachbeobachtung von Patienten mit CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL und Richter Transformation
- Rekrutierung läuftA prospective observational trial to assess treatment sequences and factors that impact
overall survival in patients with chronic lymphocytic leukaemia (CLL) treated within first-line
studies of the GCLLSG - Rekrutierung läuftBeobachtungsstudie zum Verlauf der CML unter den neuen Erstlinientherapien
- Rekrutierung läuftIvosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.
- Rekrutierung läuftA prospective non-interventional study on effectiveness and safety of Cabozantinib in real-life setting for previously treated patients with neuroendocrine tumorsEUPAS1000000752
- Rekrutierung läuftA prospective non-interventional study on effectiveness and safety of Cabozantinib in real-life setting for previously treated patients with neuroendocrine tumorsEUPAS1000000752
- Rekrutierung läuftClinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)
- Rekrutierung läuftEin Register für Befunde und Videos von Endoskopien in der Gastroenterologie
- Rekrutierung läuftProspective NIS to generate real-world-data on Effectiveness and Safety of first-line therapy with Chemotherapy combined with Durvalumab followed by maintenance therapy with Durvakumab or Durvalumab + Olaparib in endometrial Cancer